Sekiguchi Haruki    Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine    Position   Associate Professor
Language	English
Title	Comparison of Decongestion Effect between Single and Divided-dose Administration of Tolvaptan in Acute Heart Failure
Conference	The 81st Annual Scientific Meeting of the Japanese Circulation Society (JCS2017)
Promoters	Japanese Circulation Society
Conference Type	Nationwide Conferences
Presentation Type	Poster notice
Lecture Type	General
Publisher and common publisher	◎KIKUCHI Yasuhiro, JUJO Kentaro, SHIMAZAKI Kensuke, HARUKI Shintaro, ITANI Ryosuke, ARASHI Hiroyuki, SEKIGUCHI Haruki
Date	2017/03/18
Venue (city and name of the country)	Kanazawa, JAPAN
Society abstract	PROGRAM JCS 2017 334
Summary	BACKGROUNDS: Tolvaptan is generally administered once a day to patients with congestive heart failure (CHF), even it has a short half-life of 6-12 hours. The relationship between the frequency of daily administration of tolvaptan and the urine volume (UV) in acutely decompensated CHF patients is totally unclear. METHODS: This observational study included 49 consecutive patients who were urgently hospitalized due to worsening of CHF, and were treated with total of 7.5 mg daily tolvaptan. They were divided into two groups as single (QD group: 22 patients) and twice (BID group: 27 patients) administration of tolvaptan. RESULTS: Prehospital medications and 5-day total furosemide dose were similar between QD and BID groups. However, BID group showed a sustained increase in daily UV through 5 days after tolvaptan initiation, compared to baseline. In contrast, QD group achieved UV increase in only first 2 days after the initiation. As results, 5-day total increase in UV from baseline was significantly higher in BID group. Hemodynamics, decongestion degrees or renal functions were similarly changed during 5 days between the groups. However, daily furosemide dose at discharge was significantly higher in QD group (51 vs. 35 mg/day,p=0.037), and cardiovascular death was significantly lower in BID group (Log-rank: p=0.042). CONCLUSIONS: Divided-dose administration of tolvaptan may give sustainable fluid excretion to decompensated CHF patients.